A new product to cure fungal nail infection has been given the green light to go ahead.
Fungal nail infections affect millions of people across the world and can take a long time to heal.
A new therapy has been developed to address both the underlying cause of the condition, and the cosmetic issues caused by the infection; by rapidly killing the causative fungi and rapidly improving the nail’s appearance.
NovaBiotics Ltd have secured a licensing deal for their fungal treatment (NP213 peptide) to market the product globally.
Dr Deborah O’Neil of NovaBiotics, said: “We are delighted to have secured not only the most appropriate commercial partner, but also the best route to market for a nail fungus product based on NP213.
“The licensing deal for NP213 is a key revenue-generating inflexion point for NovaBiotics and we look forward to a very successful long-term commercial collaboration with our new partner.”
“NovaBiotics has reached an incredibly exciting stage in its life cycle, not only with recent advancements in our exciting portfolio of therapies for a range of infectious and respiratory disease, but with the commercial landscape for products in this space is more attractive than ever. This is evidenced by the level of recent engagement and interest in our pipeline from the investment and pharma community.”
NovaBiotics Ltd is a UK-based, clinical-stage biotechnology company focused on the design and development of immunotherapies for difficult-to-treat, medically unmet infectious diseases caused by bacteria and fungi and respiratory conditions including cystic fibrosis and viral infections such as COVID-19.